Long-Term Efficacy of a Protease Inhibitor-Sparing, Nucleoside Reverse Transcriptase Inhibitor-Limiting Antiretroviral Regimen with Nevirapine, Lamivudine, and Reduced Standard Stavudine Dosage
- 2 February 2004
- journal article
- letter
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 5 (1) , 62-64
- https://doi.org/10.1310/11pp-pg9w-fujt-64yl
Abstract
(2004). Long-Term Efficacy of a Protease Inhibitor-Sparing, Nucleoside Reverse Transcriptase Inhibitor-Limiting Antiretroviral Regimen with Nevirapine, Lamivudine, and Reduced Standard Stavudine Dosage. HIV Clinical Trials: Vol. 5, No. 1, pp. 62-64.Keywords
This publication has 2 references indexed in Scilit:
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- Evidence of Nucleoside Analogue Reverse Transcriptase Inhibitor–Associated Genetic and Structural Defects of Mitochondria in Adipose Tissue of HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002